A Phase 1b/2 Trial of AMG 386 in Combination With Pemetrexed and Carboplatin as First Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer

Trial Profile

A Phase 1b/2 Trial of AMG 386 in Combination With Pemetrexed and Carboplatin as First Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Jun 2016

At a glance

  • Drugs Trebananib (Primary) ; Carboplatin; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 24 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 14 Aug 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Nov 2015 to 1 Feb 2016.
    • 14 Aug 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 Aug 2015 to 1 Feb 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top